Biotechnology News and Research

RSS

Tikcro reports net loss of $30,000 for first quarter 2011

Tikcro Technologies Ltd. today reported results for the first quarter ended March 31, 2011.

7 Jun 2011

ITI receives FDA clearance for new Q fever assay kit

This week the U.S. Food and Drug Administration cleared the first nucleic acid amplification In vitro diagnostic (IVD) test that detects Coxiella burnetii, the bacteria that causes Q fever.

7 Jun 2011

Life Technologies develops qPCR-based accurate test to detect E. coli

Life Technologies Corporation today announced that it has developed a custom test (assay) to accurately detect the E. coli bacterium that has killed at least 22 people and affected more than 2,100 worldwide, including four new cases reported in the United States. Shipments of the TaqMan® E. coli 0104 Detection Kit to test foods thought to be associated with the outbreak are now in Europe.

6 Jun 2011

Generex not to proceed with acquisition of interest in Global Medical Direct

Generex Biotechnology Corporation today announced that the Company, together with Global Medical Direct, Inc. and its stockholders, have mutually decided not to proceed with the Company's previously announced acquisition of a 51% interest in GMD.

6 Jun 2011

Genesis Biopharma expands clinical focus to develop Contego for Stage IV metastatic melanoma

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced an expanded clinical focus to include an autologous cell therapy product candidate, Contego™, for the treatment of Stage IV metastatic melanoma.

6 Jun 2011

Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation

Adolor Corporation today announced that it has completed enrollment in its Phase 2 clinical evaluation of ADL5945 in chronic, non-cancer pain patients with opioid-induced constipation (OIC).

6 Jun 2011

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

Biogen Idec today announced the findings from a randomized, multicenter, dose-blinded clinical trial that evaluated the effect of AVONEX dose titration, or gradual dose escalation, on flu-like symptoms associated with the therapy.

6 Jun 2011

United Therapeutics completes oral treprostinil Phase 3 trial on pulmonary arterial hypertension

United Therapeutics Corporation announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).

6 Jun 2011

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange, signed today an agreement to spin off its ophthalmic indications to a US based public company, Denali Concrete Management Inc.

6 Jun 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech, a member of the Roche Group, today announced results from OCEANS, a Phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

6 Jun 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation at the ASCO 2011 Annual Meeting in Chicago.

6 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

ImaginAb, GE Healthcare sign master research deal to develop new PET diagnostic imaging agents

GE Healthcare Ltd. and ImaginAb, Inc. have executed a master research agreement around the development of new PET (Positron Emission Tomography) diagnostic imaging agents based on ImaginAb's antibody fragment technology. The agreement is launched with an initial exclusive collaboration around a novel cardiovascular target.

6 Jun 2011

ImmunoGen's SAR3419 Phase I trial data on B-cell non-Hodgkin's lymphoma presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the presentation of favorable clinical data for SAR3419 in the treatment of B-cell non-Hodgkin's lymphoma (NHL).

6 Jun 2011

Bharat Biotech announces the pricing for ROTAVAC vaccine

Bharat Biotech today announced the price of ROTAVAC India’s first indigenously developed Rotavirus Vaccine. The vaccine will be sold to global public markets, Governments worldwide including UN procurement agencies at a price of US $ 1.0. Bharat Biotech hopes its new vaccine will help prevent part of the ~ 500,000 child deaths each year caused due to rotavirus diarrhea and improve access to better, affordable rotavirus vaccines.

6 Jun 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

6 Jun 2011

Preliminary data from Ion PGM sequencer reveals German E. coli outbreak is a new hybrid strain

Life Technologies Corporation today announced that preliminary data from DNA sequencing performed in cooperation with the University Hospital Muenster, Germany, on the Ion Personal Genome Machine strongly suggests that the bacterium at the root of the deadly outbreak in Germany is a new hybrid type of pathogenic E. coli strains.

4 Jun 2011

Biotechnology News and Research

Tikcro reports net loss of $30,000 for first quarter 2011

ITI receives FDA clearance for new Q fever assay kit

Life Technologies develops qPCR-based accurate test to detect E. coli

Generex not to proceed with acquisition of interest in Global Medical Direct

Genesis Biopharma expands clinical focus to develop Contego for Stage IV metastatic melanoma

Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

United Therapeutics completes oral treprostinil Phase 3 trial on pulmonary arterial hypertension

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

ImaginAb, GE Healthcare sign master research deal to develop new PET diagnostic imaging agents

ImmunoGen's SAR3419 Phase I trial data on B-cell non-Hodgkin's lymphoma presented at ASCO 2011

Bharat Biotech announces the pricing for ROTAVAC vaccine

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Preliminary data from Ion PGM sequencer reveals German E. coli outbreak is a new hybrid strain

BGI genome sequencing identifies new super-toxic bacteria as cause of current European epidemic

Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC

Key findings from Phase I clinical trial of CPI-613 in AML to be presented at ASCO 2011

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News